P. falciparum Malaria: Developing a Synthetic Subunit Candidate Vaccine

Malaria is one of the most serious infectious diseases of humans, infecting 5–10% of the world’s population, with 300–600 million clinical cases and more than 2 million deaths annually. Moreover, malaria is a major social and economic burden in endemic areas. In recent years, malaria has spread at an alarming rate owing to the increasing resistance of the parasite to drugs, and the resistance of mosquitoes to insecticides. Therefore, new approaches to combat malaria are urgently needed, and a vaccine is predicted to have the greatest impact in addition to being the most cost-effective control measure.

Vaccine Development

One approach is to design a subunit vaccine that incorporates several malaria protein antigens for which there is evidence of protective immunity from epidemiological data or experimental animal challenge models. Development of such subunit vaccines is critically dependent on the availability of an antigen delivery system to drive suitable protein antigen-specific immune responses in humans. Vaccine formulations have to be highly effective, human-compatible and safe. Production of synthetic or recombinant proteins that stably mimic the native structure of the corresponding malaria antigens to induce effective humoral immune responses is a further major challenge.

Our research

We are addressing both problems by developing synthetic peptide structures that induce cross-reactive antibodies against the parent malaria proteins and by coupling them to the surface of immunopotentiating reconstituted influenza virosomes (IRIVs). In addition we are evaluating the use of so fare uncharacterized predicted proteins of Plasmodium falciparum as potential new candidate vaccine antigens.


Abdikadir M.I. Public health and economic importance of livestock diseases with the emphasis on zoonoses including brucellosis, Q-fever and Rift Valley Fever in Somali region, Ethiopia. Basel: Univ. Basel, 2021. PhD Thesis, University of Basel, Faculty of Science

AbouZahr C et al. The COVID-19 pandemic: Effects on civil registration of births and deaths and on availability and utility of vital events data. Am J Public Health. 2021;111(6):1123-1131. DOI: 10.2105/AJPH.2021.306203

Addo S.O et al. Trends in extrapulmonary TB cases at three teaching hospitals in Ghana, 2008-2017. Public Health Action. 2021;11(1):26-32. DOI: 10.5588/pha.20.0061

Adegnika A.A et al. Embed capacity development within all global health research. BMJ Glob Health. 2021;6(2):e004692. DOI: 10.1136/bmjgh-2020-004692

Aebi N.J et al. Can big data be used to monitor the mental health consequences of COVID-19?. Int J Public Health. 2021;66:633451. DOI: 10.3389/ijph.2021.633451

Agboli E, Zahouli J.B.Z, Badolo A, Jost H. Mosquito-associated viruses and their related mosquitoes in West Africa. Viruses. 2021;13(5):891. DOI: 10.3390/v13050891

Agorinya I.A et al. Effect of specificity of health expenditure questions in the measurement of out-of-pocket health expenditure: evidence from field experimental study in Ghana. BMJ Open. 2021;11:e042562. DOI: 10.1136/bmjopen-2020-042562

Aikins M, Tabong P.T, Salari P, Tediosi F, Asenso-Boadi F.M, Akweongo P. Positioning the national health insurance for financial sustainability and universal health coverage in Ghana: a qualitative study among key stakeholders. PLoS One. 2021;16(6):e0253109. DOI: 10.1371/journal.pone.0253109

Akweongo P, Aikins M, Wyss K, Salari P, Tediosi F. Insured clients out-of-pocket payments for health care under the national health insurance scheme in Ghana. BMC Health Serv Res. 2021;21:440. DOI: 10.1186/s12913-021-06401-8

Akweongo P, Chatio S.T, Owusu R, Salari P, Tediosi F, Aikins M. How does it affect service delivery under the National Health Insurance Scheme in Ghana? Health providers and insurance managers perspective on submission and reimbursement of claims. PLoS One. 2021;16(3):e0247397. DOI: 10.1371/journal.pone.0247397